

## DAFTAR PUSTAKA

1. Zhao R, Dai Y, Li X, Zhu C. Construction and validation of a nomogram for non small cell lung cancer patients with liver metastases based on a population analysis. *Sci Rep.* 2022;12(1):1–10.
2. Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. *Mol Clin Oncol.* 2015 Jan;3(1):217–21.
3. Chai X, Yinwang E, Wang Z, Wang Z, Xue Y, Li B, et al. Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value. *Front Oncol.* 2021;11(1):1–15.
4. Jiang C, Zhao M, Hou S, Hu X, Huang J, Wang H, et al. The Indicative Value of Serum Tumor Markers for Metastasis and Stage of Non-Small Cell Lung Cancer. *Cancers (Basel).* 2022 Oct;14(20):1–10.
5. Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, et al. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. *Ann Oncol Off J Eur Soc Med Oncol.* 2019 Jul;30(7):1088–95.
6. Madathil RJ, Tabatabai A, Rabin J, Menne AR, Henderson R, Mazzeffi M, et al. Thromboelastometry and D-Dimer Elevation in Coronavirus-2019. Vol. 34, *Journal of cardiothoracic and vascular anesthesia.* United States; 2020. p. 3495–6.
7. Dai H, Zhou H, Sun Y, Xu Z, Wang S, Feng T, et al. D-dimer as a potential clinical marker for predicting metastasis and progression in cancer. *Biomed reports.* 2018 Nov;9(5):453–7.
8. Guo J, Gao Y, Gong Z, Dong P, Mao Y, Li F, et al. Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) Patients. Wang B, editor. *Biomed Res Int.* 2021;3(1):1–11.
9. Diao D, Wang Z, Cheng Y, Zhang H, Guo Q, Song Y, et al. D-Dimer: Not Just an Indicator of Venous Thrombosis but a Predictor of Asymptomatic Hematogenous Metastasis in Gastric Cancer Patients. *PLoS One.* 2014 Jul 1;9(7):1–8.
10. Xiong R, Zhao Z, Lu H, Ma Y, Zeng H, Chen Y. Asthma Patients Benefit More Than Chronic Obstructive Pulmonary Disease Patients in the Coronavirus Disease 2019 Pandemic. *Front Med.* 2021;8:12–9.
11. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. *Clin Chest Med.* 2011 Dec;32(4):605–44.
12. Zhu T, Bao X, Chen M, Lin R, Zhuyan J, Zhen T, et al. Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis. *Front Oncol.* 2020;10(1):1–11.
13. Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N, et al. Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts; studies. *Lancet Reg Heal – Eur.* 2022 Nov 1;22(1):1–12.
14. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper

- WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer*. 2022 Mar;17(3):362–87.
15. Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, et al. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. *J Pers Med*. 2021;11(11):1–18.
  16. Milovanovic IS, Stjepanovic M, Mitrovic D. Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: An autopsy study. *Ann Thorac Med*. 2017;12(3):191–8.
  17. Lababede O, Meziane MA. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. *Oncologist*. 2018 Jul;23(7):844–8.
  18. Shan Q, Fan Y, Guo J, Han X, Wang H, Wang Z. Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: A large SEER-based study. *PeerJ*. 2019;7(1–8):e7822.
  19. Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S, et al. Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. Vol. 12, Case reports in oncology. Switzerland; 2019. p. 728–36.
  20. Valastyan S, Weinberg RA. Tumor Metastasis: Molecular Insights and Evolving Paradigms. *Cell*. 2011 Oct 14;147(2):275–92.
  21. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. *Signal Transduct Target Ther*. 2020;5(1):1–12.
  22. Lo U-G, Lee C-F, Lee M-S, Hsieh J-T. The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression. *Int J Mol Sci*. 2017 Sep;18(10):1–10.
  23. Feng Z, Wu J, Lu Y, Chan Y-T, Zhang C, Wang D, et al. Circulating tumor cells in the early detection of human cancers. *Int J Biol Sci*. 2022;18(8):3251–65.
  24. Fabricius H-Å, Starzonek S, Lange T. The Role of Platelet Cell Surface P-Selectin for the Direct Platelet-Tumor Cell Contact During Metastasis Formation in Human Tumors. *Front Oncol*. 2021;11(1):1–7.
  25. Strilic B, Offermanns S. Intravascular Survival and Extravasation of Tumor Cells. *Cancer Cell*. 2017 Sep;32(3):282–93.
  26. Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. *Nature*. 2016 Jan;529(7586):298–306.
  27. Jiang M, Jin S, Han J, Li T, Shi J, Zhong Q, et al. Detection and clinical significance of circulating tumor cells in colorectal cancer. *Biomark Res*. 2021 Nov;9(1):1–16.
  28. Palta S, Saroa R, Palta A. Overview of the coagulation system. *Indian J Anaesth*. 2014 Sep;58(5):515–23.
  29. Sang Y, Roest M, de Laat B, de Groot PG, Huskens D. Interplay between platelets and coagulation. *Blood Rev*. 2021 Mar;46(1):1–8.
  30. Loof TG, Deicke C, Medina E. The role of coagulation/fibrinolysis during *Streptococcus pyogenes* infection. *Front Cell Infect Microbiol*. 2014;4(1):1–

- 6.
31. Weisel JW, Litvinov RI. Fibrin Formation, Structure and Properties. *Subcell Biochem.* 2017;82:405–56.
  32. Ryu SH, Min SW, Kim JH, Jeong HJ, Kim GC, Kim DK, et al. Diagnostic Significance of Fibrin Degradation Products and D-Dimer in Patients With Breast Cancer-Related Lymphedema. *Ann Rehabil Med.* 2019 Feb;43(1):81–6.
  33. Bayleyegn B, Adane T, Getawa S, Aynalem M, Kifle ZD. Coagulation parameters in lung cancer patients: A systematic review and meta-analysis. *J Clin Lab Anal.* 2022 Jul 1;36(7):1–9.
  34. Linkins L-A, Takach Lapner S. Review of D-dimer testing: Good, Bad, and Ugly. *Int J Lab Hematol.* 2017 May;39 Suppl 1:98–103.
  35. Giannitsis E, Mair J, Christersson C, Siegbahn A, Huber K, Jaffe AS, et al. How to use D-dimer in acute cardiovascular care. *Eur Hear journal Acute Cardiovasc care.* 2017 Feb;6(1):69–80.
  36. Innocenti F, Lazzari C, Ricci F, Paolucci E, Agishev I, Pini R. D-Dimer Tests in the Emergency Department: Current Insights. *Open Access Emerg Med.* 2021;13(1):465–79.
  37. Bounds EJ, Kok SJ. D Dimer. In: *StatPearls.* Treasure Island (FL); 2023. p. 1–5.
  38. Stone J, Hangge P, Albadawi H, Wallace A, Shamoun F, Knuttien MG, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. *Cardiovasc Diagn Ther.* 2017 Dec;7(3):276–84.
  39. Lippi G, Franchini M, Targher G, Favaloro EJ. Help me, Doctor! My D-dimer is raised. *Ann Med.* 2008;40(8):594–605.
  40. Kabrhel C, Mark Courtney D, Camargo CAJ, Plewa MC, Nordenholz KE, Moore CL, et al. Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. *Acad Emerg Med Off J Soc Acad Emerg Med.* 2010 Jun;17(6):589–97.
  41. Pulivarthi S, Gurram MK. Effectiveness of d-dimer as a screening test for venous thromboembolism: an update. *N Am J Med Sci.* 2014 Oct;6(10):491–9.
  42. Lucotti S, Muschel RJ. Platelets and Metastasis: New Implications of an Old Interplay. *Front Oncol.* 2020;10(1):1–15.
  43. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. *Nat Rev Cancer.* 2011 Feb;11(2):123–34.
  44. Smith SA, Travers RJ, Morrissey JH. How it all starts: Initiation of the clotting cascade. *Crit Rev Biochem Mol Biol.* 2015;50(4):326–36.
  45. Chen C, Li J, Li J, Wang X, Wang X, Du N, et al. Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer. *Ann Transl Med.* 2020 Sep;8(18):1–7.
  46. Faiz Ahmed F, Tayyab M, Khalid A, Aslam M, Faiz MF. D-Dimer; A Potential Clinical Marker for Predicting Metastasis & Stages in Lung Cancer. *LOJ Phar & Cli Res* 1 (2)-2018. *LOJPCR MS ID.* 2019;108(1):1–3.
  47. Yuan Y, Zhong H, Ye L, Li Q, Fang S, Gu W, et al. Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-

- analysis. *BMC Pulm Med*. 2020 Apr;20(1):1–9.
48. Escobar Álvarez Y, de Las Peñas Bataller R, Perez Altozano J, Ros Martínez S, Sabino Álvarez A, Blasco Cordellat A, et al. SEOM clinical guidelines for anaemia treatment in cancer patients (2020). *Clin Transl Oncol*. 2021 May;23(5):931–9.
  49. Chung P-S, Tsai K-Z, Lin Y-P, Lin Y-K, Lin G-M. Association between Leukocyte Counts and Physical Fitness in Male Military Members: The CHIEF Study. *Sci Rep*. 2020 Apr;10(1):1–7.
  50. Tamási L, Horváth K, Kiss Z, Bogos K, Ostoros G, Müller V, et al. Age and Gender Specific Lung Cancer Incidence and Mortality in Hungary: Trends from 2011 Through 2016. *Pathol Oncol Res*. 2021;27(1):598–612.
  51. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. *Contemp Oncol (Poznan, Poland)*. 2021;25(1):45–52.
  52. Andarini S, Syahrudin E, Aditya N, Zaini J, Kurniawan FD, Ermayanti S, et al. Indonesian Society of Respiriology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia. *Respirol Indones*. 2023;43(2):144–50.
  53. Andriani R, Rosewitasari J, Hanif MA, Mulawarman A, Kurniawati SA, Fachri A. Factors Affecting 2-Year Survival in Patients With Non-Small Cell Lung Cancer Brain Metastases: Evidence from Indonesia's National Cancer Center, Jakarta, Indonesia. *Clin Med Insights Oncol*. 2023;17:1–8.
  54. Ernawati Y, Ermayanti S, Herman D, Russilawati R. Faktor Risiko Kanker Paru pada Perempuan yang Dirawat di Bagian Paru RSUP Dr. M. Djamil Padang dan RSUD Solok: Penelitian Case Control. *J Kesehat Andalas*. 2019;8(2):1–8.
  55. Ma Z, Zhu C, Wang H, Ji M, Huang Y, Wei X, et al. Association between biological aging and lung cancer risk: Cohort study and Mendelian randomization analysis. *iScience*. 2023;26(3):12–9.
  56. Ermayanti S, Afriani A, Nikmawati S, Russilawati R, Medison I, Suyastri S. Gender Disparities in Their Effects on Characteristics and Prognostics of Lung Cancer Patients in Pulmonary Ward of Dr. M Djamil Hospital, Padang. *Respirologi Indones*. 2021;41(4):245–51.
  57. Tarigan SP, Soeroso NN, Tumanggor CAK, Gani S, Pradana A. Clinical Profile of Male Patients with Non-Small Cell Lung Cancer in Adam Malik General Hospital, Medan, Indonesia. *Open access Maced J Med Sci*. 2019 Aug;7(16):2612–4.
  58. Wang B-Y, Huang J-Y, Chen H-C, Lin C-H, Lin S-H, Hung W-H, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. *J Cancer Res Clin Oncol*. 2020;146(1):43–52.
  59. Suraya A, Nowak D, Sulistomo AW, Icksan AG, Berger U, Syahrudin E, et al. Excess Risk of Lung Cancer Among Agriculture and Construction Workers in Indonesia. *Ann Glob Heal*. 2021;87(1):1–8.
  60. Sutandyo N, Suratman E. Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia. *Acta Med Indones*. 2018;50(4):291–8.
  61. Soeroso NN, Tanjung MF, Afiani D, Pradana A, Tarigan SP, Wahyuni AS.

- Procalcitonin Level in Non-Small Cell Lung Cancer Patients among Indonesian Population. *Open access Maced J Med Sci.* 2018;6(11):2123–7.
62. Syahrudin E, Wulandari L, Sri Muktiati N, Rima A, Soeroso N, Ermayanti S, et al. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. *Lung Cancer (Auckland, NZ).* 2018;9:25–34.
  63. Sehgal K, Gill RR, Widick P, Bindal P, McDonald DC, Shea M, et al. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. *JAMA Netw Open.* 2021;4(2):1–11.
  64. Barlow M, Hamilton W, Ukoumunne OC, Bailey SER. The association between thrombocytosis and subtype of lung cancer: a systematic review and meta-analysis. *Transl Cancer Res.* 2021;10(3):1249–60.
  65. Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. *Blood.* 2014;124(2):184–7.
  66. Kang HS, Shin AY, Yeo CD, Park CK, Kim JS, Kim JW, et al. Clinical significance of anemia as a prognostic factor in non-small cell lung cancer carcinoma with activating epidermal growth factor receptor mutations. *J Thorac Dis.* 2020;12(5):1895–902.
  67. Zhang Y-H, Lu Y, Lu H, Zhang M-W, Zhou Y-M, Li X-L, et al. Pre-treatment hemoglobin levels are an independent prognostic factor in patients with non-small cell lung cancer. *Mol Clin Oncol.* 2018 Jul;9(1):44–9.
  68. Wong JYY, Bassig BA, Loftfield E, Hu W, Freedman ND, Ji B, et al. White Blood Cell Count and Risk of Incident Lung Cancer in the UK Biobank. *JNCI Cancer Spectr.* 2020;4(2):10–2.
  69. Abukhiran IA, Jasser J, Syrbu S. Paraneoplastic leukemoid reactions induced by cytokine-secreting tumours. *J Clin Pathol.* 2020 Jun 1;73(6):310–3.
  70. Vinas F, Ben Hassen I, Jabot L, Monnet I, Chouaid C. Delays for diagnosis and treatment of lung cancers: a systematic review. *Clin Respir J.* 2016;10(3):267–71.
  71. Wang X, Wang Z, Pan J, Lu Z-Y, Xu D, Zhang H-J, et al. Patterns of Extrathoracic Metastases in Different Histological Types of Lung Cancer. *Front Oncol.* 2020;10(1):1–10.
  72. Popper HH. Progression and metastasis of lung cancer. *Cancer Metastasis Rev.* 2016;35(1):75–91.
  73. Ward MP, E. Kane L, A. Norris L, Mohamed BM, Kelly T, Bates M, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? *Mol Cancer.* 2021;20(1):1–12.
  74. Douma RA, Tan M, Schutgens REG, Bates SM, Perrier A, Legnani C, et al. Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. *Haematologica.* 2012;97(10):1507–13.
  75. Tekeşin K, Bayrak S, Esatoğlu V, Özdemir E, Özel L, Melih Kara V. D-Dimer and Carcinoembryonic Antigen Levels: Useful Indicators for Predicting the Tumor Stage and Postoperative Survival. Setoyama T, editor. *Gastroenterol Res Pract [Internet].* 2016;2016:4295029. Available from:

<https://doi.org/10.1155/2016/4295029>

76. Diao D, Cheng Y, Song Y, Zhang H, Zhou Z, Dang C. D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer. *BMC Cancer*. 2017 Jan;17(1):56–9.
77. Niimi K, Nishida K, Lee C, Ikeda S, Kawai Y, Sugimoto M, et al. Optimal D-Dimer Cutoff Values for Diagnosing Deep Vein Thrombosis in Patients with Comorbid Malignancies. *Ann Vasc Surg*. 2023;1(1):1–10.
78. Zhang X, Wang X, Li W, Dang C, Diao D. Effectiveness of managing suspected metastasis using plasma D-dimer testing in gastric cancer patients. *Am J Cancer Res*. 2022;12(3):1169–78.

